Literature DB >> 22057149

Lack of association between flow-mediated endothelium-dependent vasodilatation and biomarkers of endothelial dysfunction in patients with severe rheumatoid arthritis.

Miguel A González-Gay, Carlos González-Juanatey, José A Miranda-Filloy, Maria T García-Unzueta, Javier Llorca.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057149     DOI: 10.1007/s00296-011-2254-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  10 in total

1.  Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab.

Authors:  C Gonzalez-Juanatey; J Llorca; A Sanchez-Andrade; C Garcia-Porrua; J Martin; M A Gonzalez-Gay
Journal:  Clin Exp Rheumatol       Date:  2006 May-Jun       Impact factor: 4.473

Review 2.  Rheumatoid arthritis: a disease associated with accelerated atherogenesis.

Authors:  Miguel A Gonzalez-Gay; Carlos Gonzalez-Juanatey; Javier Martin
Journal:  Semin Arthritis Rheum       Date:  2005-08       Impact factor: 5.532

3.  Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis.

Authors:  R De Caterina; G Basta; G Lazzerini; G Dell'Omo; R Petrucci; M Morale; F Carmassi; R Pedrinelli
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-11       Impact factor: 8.311

4.  Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study.

Authors:  S J Hwang; C M Ballantyne; A R Sharrett; L C Smith; C E Davis; A M Gotto; E Boerwinkle
Journal:  Circulation       Date:  1997-12-16       Impact factor: 29.690

5.  Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis.

Authors:  M A Gonzalez-Gay; M T Garcia-Unzueta; J M De Matias; C Gonzalez-Juanatey; C Garcia-Porrua; A Sanchez-Andrade; J Martin; J Llorca
Journal:  Clin Exp Rheumatol       Date:  2006 Jul-Aug       Impact factor: 4.473

6.  Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy.

Authors:  Bernat Galarraga; Jill J F Belch; Tom Pullar; Simon Ogston; Faisel Khan
Journal:  J Rheumatol       Date:  2010-01-15       Impact factor: 4.666

7.  HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis.

Authors:  Carlos Gonzalez-Juanatey; Ana Testa; Alberto Garcia-Castelo; Carlos Garcia-Porrua; Javier Llorca; Juan Vidan; Ali H Hajeer; William E Ollier; Derek L Mattey; Miguel A Gonzalez-Gay
Journal:  Am J Med       Date:  2003-06-01       Impact factor: 4.965

8.  Microvascular dysfunction in rheumatoid arthritis assessed by laser Doppler anemometry: relationship to soluble adhesion molecules and extraarticular manifestations.

Authors:  Martin F Meyer; Olga Schmidt; Bernhard Hellmich; Helmut Schatz; Harald H Klein; Jürgen Braun
Journal:  Rheumatol Int       Date:  2007-06-29       Impact factor: 2.631

9.  Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease.

Authors:  Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Arthritis Res Ther       Date:  2011-06-22       Impact factor: 5.156

10.  Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis.

Authors:  Patrick H Dessein; Barry I Joffe; Sham Singh
Journal:  Arthritis Res Ther       Date:  2005-03-24       Impact factor: 5.156

  10 in total
  1 in total

1.  Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration.

Authors:  Ewa Klimek; Anna Skalska; Beata Kwaśny-Krochin; Andrzej Surdacki; Joanna Sulicka; Mariusz Korkosz; Danuta Fedak; Izabella Kierzkowska; Barbara Wizner; Tomasz K Grodzicki
Journal:  Mediators Inflamm       Date:  2014-03-03       Impact factor: 4.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.